European regions network for Health Research & Innovation - - PowerPoint PPT Presentation

Joaquin Guinea, INNOVATEC

European regions network for Health Research & Innovation (RegHealth-RI) project

Brussels, 17th November, 2014 RegHealth-RI Coordinator RegHealth-RI PROJECT KICK-OFF MEETING 17-18 November 2014, Brussels

HCO-14-2014--Bridging the divide in European health research and innovation

http://ec.europa.eu/research/participants/portal/desktop/en/opportu nities/h2020/topics/2217-hco-14-2014.html

2 4 6 8 10 Finland Sweden Denmark Germany Austria Slovenia Estonia France Belgium Netherlands United Kingdom Ireland Czech Republic Portugal Luxembourg Spain Italy Hungary Lithuania Croatia Poland Malta Latvia Slovakia Greece Bulgaria Cyprus Romania Switzerland Iceland Norway Turkey Serbia

Capital region National average Other NUTS regions *Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)

Regional disparities in R&D intensity, by NUTS 2 regions, 2011*

(total R&D expenditure as a % of GDP)

*Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)

Regional disparities in R&D intensity, by NUTS 2 regions, 2011*

(total R&D expenditure as a % of GDP)

Regional disparities in competitiveness for the innovation sub-index, by NUTS 2 regions, 2013 (1) (EU-28 = 0)

*Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)

Regional competitiveness for selected dimensions of the innovation sub-index, by NUTS 2 regions, 2013

*Source: Eurostat regional yearbook 2014 (http://epp.eurostat.ec.europa.eu/portal/page/portal/publications/regional_yearbook)

European Commission. (2013). Research and Innovation Performance in EU Member States and Associated Countries 2013 ( http://ec.europa.eu/research/innovation-union/pdf/state-of-the-

union/2012/innovation_union_progress_at_country_level_2013.pdf)

HEALTH - Scientific publications (2000-09) and Technological production (EPO

patents, 2000-10) in EU Regions

• TO REDUCE THE GAPS IN HEALTH R&I ACROSS THE EU

REGIONS

• TO INCREASE THE PARTICIPATION IN HORIZON2020
• TO FACILITATE SYNERGIES BETWEEN HORIZON2020 AND

STRUCTURAL FUNDS

REGHEALTH-RI MAIN OBJECTIVES

TO PROPOSE NEW INITIATIVES AND CONCRETE APPROACHES TO EU, NATIONAL AND REGIONAL DECISION-MAKERS:

• Sociedad para el Fomento de la Innovacion Tecnológica (Innovatec) - Coordinator
• European Regional and Local Health Authorities (EUREGHA)
• University of Trieste
• Prof. Jerzy Duszynski, former Deputy Minister of Science of Poland. At present he is the head of

the laboratory of Bioenergetics, Nencki Institute of Experimental Biology, Warsaw – Poland

• Prof. Toivo Maimets, former Minister of Education and Research of Estonia. At present he is Prof.

at the Univ. of Tartu and member of the Estonian Research Council Gov. Board – Estonia

• Mrs. Illiana Paunova, Chairperson of the Association of the Research-based Pharmaceutical

Manufacturers in Bulgaria and General Manager of GlaxoSmithKline Bulgaria – Bulgaria

• Prof. Ana Stavljenic-Rukavina, former Minister of Health of Croatia. At present she is Dean at

DIU Libertas International University, Zagreb – Croatia

• Mrs. María José Muñoz Martínez, Directorate General of Community Funds, Ministry of Finance

and Public Administration – Spain

• Prof. Jonathan Watson, Co-Founder INTEGRATE; Special Professor of Health & Public Policy, Univ.
• f Nottingham; External Expert to DG REGIO; Executive Director Health ClusterNet – UK

ADVISORY BOARD MEMBERS PROJECT PARTNERS

RegHealth-RI

• August Kirchenstein Institute of Microbiology and Virology. Riga Stradins University – Latvia
• Business & Innovation Centre (BIC) of Epirus – Greece
• Comissão de Coordenação e Desenvolvimento Regional (CCDR) do Algarve – Portugal
• Democritus University of Thrace, Department of Molecular Biology and Genetics
• Estonian HealthTech Cluster – Estonia
• Estonian Research Council (Horizon 2020 National Contact Point on Health) – Estonia
• Fundación Pública Andaluza Progreso y Salud – Spain
• Inkubator d.o.o. Sežana – Slovenia
• Innovative Pharmaceutical Industry Association (IFPA) of Lithuania – Lithuania
• Intermediate Managing Authority Region of Western Greece – Greece
• Marche Region. Department of Research and Innovation – Italy
• Marshall Office of Lubelskie Voivodeship, Dep. of Economy and Innovation – Poland
• Marshal's Office Świętokrzyskie. Office of Innovation – Poland
• MidTECH. National Health Service (NHS) Innovation Hub For The West Midlands – UK
• Ministry of Education, Science and Sport – Slovenia
• Ministry of Education and Science, Study and Research Administration – Latvia
• National Documentation Centre – Greece
• North-East Regional Development Agency (ADR Nord-Est) – Romania
• Nutrition, Health and Longevity (NHL) Cluster (Lille) – France
• Ovidius University / Clinical Hospital of Infectious Diseases, Constanța – Romania
• Research Park, Autonomous University of Barcelona – Spain
• Slovak Association of Research Based Pharmaceutical Companies (SAFS) – Slovakia
• South Transdanubian Regional Innovation Agency – Hungary
• St. Anne's University Hospital in Brno-Int. Clinical Research Center –- Czech Republic

RegHealth-RI ASSOCIATE PARTNERS

WP4: Dissemination activities

The European regions network for Health Research and Innovation (RegHealth-RI) WORK PLAN SUMMARY: Planned Work Packages (WPs) and Events

1st Year

WP1: State of the Art of health R&I in EU regions

and identification and analysis of determinants influencing its performance and progression

WP5: Management

2nd Year

2nd Workshop: “New approaches for bridging the divide in health R&I in the EU regions”

WP2: Creation of a NETWORKING PLATFORM and organization of three Workshops to discuss the divide

in European Health R&I and possible solutions

3rd Workshop: “HORIZON 2020: Synergies with Structural Funds and new ways for widening the participation”

WP3: 1st

European Conference: “Bridging the divide in European health R&I”

1st European Conference: “BRIDGING THE

DIVIDE IN EUROPEAN HEALTH R&I”

1st Workshop: “Analysis of Health R&I in less performing EU regions: Present situation, possible causes and influencing factors”

Starting date: 01-Nov-2014

WP2

• WORKSHOPS REPORTS
• PRESENTATIONS
• PRESS RELEASES
• POLICY BRIEFS

WS1: ‘”Analysis of Health R&I in less performing EU regions: Present situation and new perspectives’”

Planned Deliverables

WS2: “New approaches for bridging the divide in health R&I in the EU regions” WS3: “Horizon 2020: Synergies with Structural Funds and new ways for widening the participation” WP1 State of the Art of the health research and innovation (R&I) in less performing regions Launching the REGHEALTH-RI Networking Platform WP3 1st European Conference - ‘Bridging the divide in European health R&I’

• CONFERENCE REPORT
• PRESENTATIONS
• PRESS RELEASES
• POLICY BRIEFS
• WEBSITE
• NETWORKING TOOLS
• FINAL PUBLISHABLE

SUMMARY REPORT

Universities and R&D centers Health & Biotech clusters Companies (pharma, biotech, etc.)

• Sci. & Tech Parks,

Incubators, etc.

National and Regional authorities

EXPECTED IMPACT ON:

• WIDENING PARTICIPATION
• BRIDGING THE INNOVATION DIVIDE
• SYNERGIES BETWEEN H2020 AND

STRUCTURAL FUNDS

POLICY AND DECISSION MAKING

EU : DG REGIO DG Research & Inn.

DISSEMINATION (WP4)

• STATE OF THE ART REPORT
• ACADEMIC DOCUMENTS

RegHealth-RI EXPECTED IMPACT

• Determining the State of the Art of the

health Research and Innovation (R&I) activities in EU regions looking for key factors, specific differences and common patterns which could explain the differences between them

• Designing and developing indicators

(qualitative and quantitative) to measure the degree of development of the health R&I across the European regions

• To elaborate a detailed report depicting

the current situation as well as common patterns, differences or factors influencing on the health R&I across EU regions

WP1: STATE OF THE ART OF HEALTH RESEARCH AND INNOVATION (R&I) IN EU REGIONS AND IDENTIFICATION AND ANALYSIS OF DETERMINANTS INFLUENCING ITS PERFORMANCE AND PROGRESSION MAIN OBJECTIVES

Health Definition/Classification

DATA SOURCES EVIDENCE- BASED ANALYSIS PROCESSING

R&D EXPENDITURE

• EUROSTAT

HEALTH DATA ON INFRAESTRUCTURES, TRAINING, CLINICAL TRIALS, ETC.

• GOVERNMENT WEBS

(MINISTRY OF HEALTH,

• SCI. & RESEARCH…)
• INSTITUTIONAL

REPOSITORIES

• PUBLIC REPORTS
• OTHERS

Data Retrieval Health Delineation: Search Strategies

Regional Aggregations National Disaggregations DATA FORMATTING

• Tabulation,
• Correction
• Etc…

REPORT: State of the Art of health Research

and Innovation (R&I) in EU regions and identification and analysis of determinants influencing its performance and progression OUTPUT Multivariate Analysis: Cluster, PCA… Descriptive Stats: Means, Variance… Linear Regression Analysis

Development of Indicators HEALTH / BIOTECH PUBLICATIONS AND PATENTS - (DG RES. & INNOV.)

• EC (2013). Research

and innovation performance in EU Member States and associated countries – Innovation Union progress at country level RIS3

• Eye@RIS3

• The launching of the European regions network for Health Research and Innovation

Platform (RegHealth-RI Platform, tentative name) is an important goal of the project

• Will be composed of actors from different EU organizations with interest and

targets in promoting health R&I at regional, national or European level.

• The main objective of this networking platform will be to promote and facilitate

the communication between network members to enrich the dialogue, the feedback and exchange of opinions and experiences among the members.

• Several networking tools like the network webpage, discussion forums,

collaborative work tools (wiki or similar), social network tools and intranet, will be implemented to facilitate the communication. The intranet of the network website could include repositories including the following types of documents:

LAUNCH OF A NETWORKING PLATFORM

• Examples of successful approaches to obtain synergies between H2020 and SF
• Good practices for health/ biotech cluster development.
• Successful regional programmes promoting collaboration between academic centres and

companies in the health sector.

• Good practices for academic spin-off promoting programmes.
• Key points to take into account when promoting technology transfer between academic

research centres and private companies in the health sector.

• Methodologies and tools for identifying and assessing the impact of the R&I regional

programmes addressing the health sector.

Consortium

Potential Members

H2020 NCPs Health & Biotech Clusters

• Sci. & Tech

Parks, Incubators, etc. National and Regional authorities Companies (pharma, biotech, etc.) Practitioners

Initial Members (Associated Partners, etc.)

Universities and R&D centers Health & Biotech clusters H2020 NCPs Companies (pharma, biotech, etc.)

• Sci. & Tech

Parks, Incubators, etc. Practitioners Civil Society Org.

Core Partners Advisory Board Dissemination Networking

• Forums
• Wiki
• Intranet
• Flyer
• Brochure
• P. Releases
• Newsletters

Registration Form

WEBSITE

RegHealth-RI Network

Universities and R&D centers Civil Society Org. National and Regional authorities

Timing (month

from staring the project)

Title

(preliminary)

Organizer / Place

(prelim.)

Objectives of the Workshop /Conference

(preliminary)

Participants

1st Workshop 7th month Analysis of Health R&I in less performing EU regions: Present situation, possible causes and influencing factors Innovatec /Madrid

• Analyses of the regional

disparities: determin.s, common patterns, FP7 particip., RIS3 strat. etc.,

• Causes and influencing

factors: low invest. in R&D, scant infrastruct., lack of training prog., etc.

• Partners
• Assoc. Partners
• Advisory Board
• 10-15 experts /authorities

[Tot. aprox. 40-45] 2nd Workshop 13th month New approaches for bridging the divide in health R&I in the EU regions Nencki Institute /Warsaw

• Discuss and agree on

different approaches for bridging the divide in health R&I

• Partners
• Assoc. Partners
• Advisory Board
• 10-15 experts /authorities
• [Tot. aprox. 40-45]

3rd Workshop 19th month Horizon 2020: Synergies with Structural Funds and new ways for widening the participation To be decided

• Discuss and agree on

different approaches for increasing H2020: synergies with SF and for widening its participation

• Partners
• Assoc. Partners
• Advisory Board
• 10-15 experts /authorities

[Tot. aprox. 40-45] 1st European Conference 23rd month Bridging the divide in European health R&I EUREGHA / Brussels

• Analysis of the sit. of health

R&I in EU regions

• Presentation of new

approaches agreed in the Workshops for bridging the divide, incr. synergies & widening the particip.

• Partners
• Assoc. Partners
• Advisory Board
• 50-60 invited persons

included DG Research, DG Regio, DG SANCO and COST officers [Tot. aprox. 80-100]

THEMATIC WORKSHOPS AND ORGANIZATION OF THE 1ST CONFERENCE ON "BRIDGING THE DIVIDE IN EUROPEAN HEALTH R&I" (preliminary name)

• Introduction of health R&I strategies and targets in organizations representing

the regions

• State of the Art of the health R&I) in regions (advanced draft document

produced during WP1):

• Analysis of the regional disparities in terms of health research and innovation.
• Detection of common patterns and study of determinants on health R&I within the less

performing EU regions.

• Analysis of the participation of low performing European regions in health areas of FP7

program and sub-programs such as Regional Potential, Marie-Curie, etc.

• Causes and influencing factors of the regional disparities in health R&I

(preliminary ideas):

• Low investment in R&D,
• Scant R&I infrastructures,
• Lack of doctoral/master programs, etc
• Discussion and analysis of present RIS3 strategies

1st Workshop - Analysis of Health R&I in less performing EU regions:

Present situation, possible causes and influencing factors

Topics for discussion (preliminary)

• Identification of actions to reduce the gaps in the R&I on health across the EU

regions (preliminary ideas):

• Promoting science-industry co-operation and technology transfer and training
• Developing regional research infrastructure and centres of competence
• Establish new funding programs to develop and disseminate technology innovations

within the non-profit sector

• Create forums and intermediaries to facilitate the adoption and dissemination of

technology innovations

• Promote health innovation clusters for regional growth
• Support services to innovating firms: i.e. science parks or incubators
• Promoting spin-offs from research centres

2nd Workshop - New approaches for bridging the divide in health R&I in the EU regions Topics for discussion (preliminary)

• Analysis of the results of the Pillar 15 of Horizon 2020: "Spreading Excellence and

Widening Participation: Teaming, Twinning, ERA Chairs, the Policy Support Facility and the Special action from COST on Widening actions and its possible synergies with Structural Funds

• Identification of possible actions/initiatives/programmes to increase the

participation in H2020 and to facilitate synergies between H2020 and Structural Funds (preliminary ideas):

• Design H2020 work programmes taking RIS3 fields and SF implementation timelines into

account and include FP7/Horizon2020 participants from less dev. regions, to design RIS3.

• Promote actions funded by SFs to support the preparation of proposals for H2020

(search for projects/partners, writing the proposal, budget elaboration, etc.) of both Academic research centres and companies

• Promote new doctoral programmes funded by ESIF for increasing its possibilities of

additional funding in the Horizon 2020 under the Marie Skłodowska-Curie Actions

• Open Horizon 2020 strategic platforms (Joint Programming Initiatives, European

Innovation Partnerships, etc.) for regional level policy actors.

3rd Workshop - Horizon 2020: Synergies with Structural Funds and new ways for widening the participation Topics for discussion (preliminary)

1st European Conference Bridging the divide in European health R&I

A selection of the most important topics discussed during the previous workshops will be performed

Thank you very much

Joaquin Guinea, INNOVATEC joaquin.guinea@innovatec.es RegHealth-RI Coordinator